Perineural Treatment with High Mobility Group Box-1 Monoclonal Antibody Prevents Initiation of Pain-Like Behaviors in Female Mice with Trigeminal Neuropathy.

female mouse high mobility group box 1 macrophage microglia neutralizing antibody trigeminal neuropathy

Journal

Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984

Informations de publication

Date de publication:
2024
Historique:
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 21 1 2024
Statut: ppublish

Résumé

Post-traumatic trigeminal neuropathy (PTTN) is a type of chronic pain caused by damage to the trigeminal nerve. A previous study reported that pretreatment with anti-high mobility group box-1 (HMGB1) neutralizing antibodies (nAb) prevented the onset of PTTN following distal infraorbital nerve chronic constriction injury (dIoN-CCI) in male mice. Clinical evidence indicates a high incidence of PTTN in females. Although our previous study found that perineural HMGB1 is crucial in initiation of PTTN in male mice, it is currently unknown whether HMGB1 is also involved in the pathogenesis of PTTN in female mice. Therefore, in the current study, we examined the effect of anti-HMGB1 nAb on pain-like behavior in female mice following dIoN-CCI surgery. We found that dIoN-CCI surgery enhanced reactivity to mechanical and cold stimuli in female mice, which was suppressed by treatment with anti-HMGB1 nAb. Moreover, the increase in macrophages after dIoN-CCI was significantly attenuated by pretreatment with anti-HMGB1 nAb. Furthermore, anti-HMGB1 nAb treatment inhibited microglial activation in the trigeminal spinal tract nucleus. These data suggest that HMGB1 also plays a crucial role in the onset of PTTN after nerve injury in female mice. Thus, anti-HMGB1 nAb could be a novel therapeutic agent for inhibiting the onset of PTTN in female and male mice.

Identifiants

pubmed: 38246608
doi: 10.1248/bpb.b23-00729
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-226

Auteurs

Simeng Ma (S)

Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.

Yoki Nakamura (Y)

Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.

Takahiro Kochi (T)

Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.
Department of Dental Anesthesiology, Graduate School of Biomedical and Health Sciences, Hiroshima University.

Suzuna Uemoto (S)

Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.

Kazue Hisaoka-Nakashima (K)

Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.

Dengli Wang (D)

Department of Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Keyue Liu (K)

Department of Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Hidenori Wake (H)

Department of Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.
Department of Pharmacology, Faculty of Medicine, Kindai University.

Masahiro Nishibori (M)

Department of Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.
Department of Translational Research & Dug Development, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Norimitsu Morioka (N)

Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.

Classifications MeSH